What is Medicine 3.0?

What Is Medicine 3.0

Medicine 3.0 describes a shift in how health is understood and managed. It moves away from treating disease after it appears and toward identifying risk early, often before symptoms develop. The focus is not only on extending lifespan, but on preserving healthspan the period of life spent in good physical, cognitive, and emotional condition.

At its core, this model is built on two ideas. First, that most chronic diseases develop slowly over time and can be influenced earlier than traditionally assumed. Second, that individuals vary significantly in how they respond to risk, treatment, and environment, which limits the effectiveness of standardized care models (Califf and Hudson, 2021).

Medicine 3.0 is closely aligned with the principles of precision medicine, where decisions are informed by a combination of genetic, lifestyle, and environmental data. Rather than relying only on population averages, it attempts to interpret risk at an individual level.

This approach is often described through the “P4” frameworkpredictive, preventive, personalized, and participatory where patients are not passive recipients of care but active participants in managing long-term health trajectories (Hood and Flores, 2012).

In practical terms, Medicine 3.0 is less about new treatments and more about timing, interpretation, and context identifying when to act, what to monitor, and how to adjust decisions based on evolving data.

 🔗 Quick Links

• What Is Medicine 3.0
• Why It Matters Now
• How It Works
• Medicine 3.0 vs Traditional Healthcare Models
• What Medicine 3.0 Is Not
• The Medicine 3.0 Framework
• What Is Available Today
• What Is Emerging
• Evidence Layer: What the Research Indicates
• Limitations and Considerations
• Who This Is For — and Who It Is Not
• Decision Framework
• Synthesis
• Final Thoughts
• Frequently Asked Questions

Why It Matters Now

The relevance of Medicine 3.0 is largely driven by a mismatch between current healthcare systems and the nature of modern disease.

Most healthcare systems today are structured around acute intervention responding to illness once it becomes clinically visible. However, the dominant causes of mortality globally are chronic conditions such as cardiovascular disease, metabolic disorders, cancer, and neurodegeneration. These conditions typically develop over years or decades, often without clear early symptoms (The Lancet Healthy Longevity, 2021).

This creates a structural gap. By the time disease is diagnosed, meaningful intervention may already be limited.

At the same time, several developments have made earlier detection and interpretation more feasible:

• Increased access to biological data (genomics, blood markers, imaging)
• Continuous monitoring through wearable devices
• Advances in artificial intelligence for risk modeling
• Expansion of longitudinal health datasets

Together, these shifts allow for earlier signals to be detected and interpreted, even if the clinical meaning of those signals is still evolving.

There is also a demographic factor. As life expectancy increases globally, the gap between lifespan and healthspan becomes more visible. Living longer does not necessarily mean living well, and the burden of chronic disease in later life continues to rise.

Medicine 3.0 emerges within this context not as a replacement for traditional care, but as an additional layer that attempts to address timing, prevention, and long-term function more directly.

How It Works

Medicine 3.0 is best understood as a system rather than a single intervention. It operates across multiple layers, each contributing to how risk is identified, interpreted, and managed over time.

Data Layer: Continuous and Multi-Dimensional Inputs

The foundation of this model is data. This includes:

• Genetic information
• Blood-based biomarkers
• Imaging data
• Lifestyle and behavioral inputs
• Real-time physiological tracking (e.g., heart rate, sleep patterns)

Unlike traditional snapshots taken during clinical visits, this layer often involves continuous or repeated measurement, allowing patterns to emerge over time.

Interpretation Layer: From Signals to Meaning

Raw data alone has limited value without interpretation. This is where analytical frameworks and computational models are applied.

Artificial intelligence and statistical models are increasingly used to identify patterns that may indicate early disease processes or deviations from baseline health (ArXiv Authors, 2024). These models do not provide definitive answers but generate probabilistic insights suggesting where attention may be needed.

Importantly, interpretation remains an evolving challenge. Many biomarkers and signals are still being studied, and their predictive value can vary across populations.

Decision Layer: Context-Based Action

The final layer involves decision-making. This does not necessarily mean treatment. In many cases, it involves:

• Adjusting monitoring frequency
• Modifying lifestyle variables
• Investigating further through targeted diagnostics

Decisions are typically context-dependent, shaped by individual risk tolerance, baseline health, and available evidence.

Rather than a fixed protocol, this layer functions as an ongoing process of reassessment where new data informs updated interpretations, and decisions evolve accordingly.

Taken together, these layers form a system that is iterative rather than linear. Medicine 3.0 does not aim to eliminate uncertainty but to manage it more effectively over time, using structured data and interpretation to reduce blind spots in long-term health planning.

Medicine 3.0 vs Traditional Healthcare Models

A useful way to understand Medicine 3.0 is by comparing it with the system it builds upon. Traditional healthcare often referred to as Medicine 2.0 has been highly effective in acute care, infectious disease control, and surgical intervention. However, its structure is less aligned with slow-moving, multi-factorial chronic diseases.

Approach to Disease

Traditional models are largely reactive. Intervention begins once symptoms appear and a diagnosis is established. This works well for acute conditions but is less effective for diseases that develop silently over long periods.

Medicine 3.0 shifts toward a proactive orientation, where risk is assessed earlier, often before clinical thresholds are reached. The goal is not early treatment in the conventional sense, but earlier awareness and interpretation of risk signals.

Use of Data

In traditional systems, data is typically episodic collected during appointments or specific tests. Decisions are based on population-level evidence, often derived from randomized controlled trials.

Medicine 3.0 incorporates continuous and individualized data streams, including biomarkers, wearables, and longitudinal tracking. It does not replace population evidence but attempts to refine it at the individual level.

Role of the Individual

The traditional model tends to be clinician-led, with patients following prescribed pathways.

In contrast, Medicine 3.0 is more participatory. Individuals are expected to engage with their own data, understand risk factors, and take part in ongoing decision processes. This does not imply autonomy over clinical decisions, but a higher level of involvement in long-term health management.

Time Horizon

Traditional care often focuses on short- to medium-term outcomes treating current illness or managing diagnosed conditions.

Medicine 3.0 extends the horizon to decades, considering how current variables may influence future health trajectories. This introduces complexity, as long-term predictions are inherently uncertain and depend on evolving evidence.

What Medicine 3.0 Is Not

As the concept gains attention, several misconceptions have emerged. Clarifying what Medicine 3.0 is not helps reduce confusion and sets realistic expectations.

Not a Replacement for Traditional Medicine

Medicine 3.0 does not replace existing healthcare systems. Acute care, emergency medicine, and evidence-based treatment protocols remain essential. Instead, it operates as an additional layer focused on earlier stages of disease development.

Not a Defined Set of Treatments

There is no fixed list of therapies that define Medicine 3.0. It is not tied to specific interventions such as supplements, therapies, or procedures.

Rather, it is a framework for interpreting and acting on risk, which may or may not involve clinical intervention depending on context.

Not Fully Standardized

Unlike established clinical guidelines, many aspects of Medicine 3.0 are still evolving. Biomarkers, predictive models, and intervention thresholds are areas of active research.

This means variability is high across providers, and interpretations may differ. The lack of standardization is not necessarily a flaw, but it does introduce uncertainty.

Not Risk-Free

Earlier detection of risk does not automatically translate into better outcomes. In some cases, identifying risk earlier may lead to:

• Over-monitoring
• Unnecessary interventions
• Increased psychological burden

These trade-offs are part of the broader discussion around how predictive information should be used.

The Medicine 3.0 Framework: A Layered View

Understanding Medicine 3.0 as a system can be simplified through a layered framework. This helps organize its components without reducing its complexity.

Layer 1: Risk Identification

This layer focuses on detecting early signals of potential health issues. It includes:

• Biomarker testing
• Genetic screening
• Imaging and physiological measurements

The goal is not diagnosis, but identifying deviations from expected baseline patterns.

Layer 2: Risk Interpretation

Once signals are identified, they need to be contextualized. This involves:

• Comparing individual data to population benchmarks
• Using models to estimate future risk probabilities
• Evaluating interactions between multiple variables

Interpretation is probabilistic rather than definitive, and often evolves as new data becomes available.

Layer 3: Monitoring and Feedback

Medicine 3.0 relies on ongoing observation rather than one-time assessment. This layer includes:

• Continuous tracking through wearables
• Periodic re-testing of biomarkers
• Updating baselines over time

The objective is to detect changes early and refine understanding of individual health patterns.

Layer 4: Decision Context

The final layer involves translating insights into decisions. These are influenced by:

• Individual risk tolerance
• Strength of available evidence
• Time horizon of potential outcomes

Importantly, decisions are not static. They are revisited as new data and interpretations emerge, making the framework inherently dynamic.

Viewed together, these layers illustrate that Medicine 3.0 is not a single shift, but a restructuring of how health information is generated, interpreted, and applied over time.

What Is Available Today

Medicine 3.0 is often discussed as a future model, but several components already exist in practice. These are not unified into a single system. Instead, they appear as separate categories of services and tools, each addressing a different part of the framework.

Advanced Diagnostics and Biomarker Testing

A growing number of providers offer extended diagnostic panels that go beyond standard clinical testing. These may include:

• Expanded blood biomarker panels
• Hormonal profiling
• Inflammatory and metabolic markers
• Imaging for early structural changes

These tools aim to detect subclinical deviations changes that occur before disease is formally diagnosed. However, interpretation varies, and not all markers have clear clinical thresholds (López-Otín et al., 2025).

Genetic and Genomic Analysis

Genomic testing is increasingly accessible and is used to assess:

• Disease predisposition
• Drug response variability
• Inherited risk factors

Large-scale initiatives have demonstrated the potential of linking genomic data with health records to improve long-term risk modeling (Califf and Hudson, 2021). At the same time, the predictive value of many genetic findings remains probabilistic rather than deterministic.

Continuous Monitoring Technologies

Wearable devices and mobile health tools provide real-time data on:

• Heart rate and variability
• Sleep patterns
• Physical activity
• Stress indicators

This category introduces a shift from episodic measurement to continuous observation. While useful for identifying trends, the clinical meaning of many signals is still being defined.

Longevity-Focused Clinics

A number of specialized clinics now position themselves around prevention and health optimization. These often combine:

• Advanced diagnostics
• Personalized risk assessments
• Ongoing monitoring programs

However, these clinics operate in a heterogeneous and partially unregulated space, with varying standards of evidence and clinical rigor. Some interventions offered may still be experimental or lack long-term validation (The Lancet Healthy Longevity, 2021).

Data Integration Platforms

An emerging category involves platforms designed to aggregate and interpret health data across sources. These systems aim to:

• Combine diagnostics, wearables, and history
• Provide structured insights
• Support longitudinal tracking

The effectiveness of these platforms depends largely on the quality of underlying data and the validity of their analytical models.

Taken together, what exists today is fragmented but expanding. The components of Medicine 3.0 are present, but integration into a cohesive system remains limited.

What Is Emerging

Beyond current offerings, several developments are shaping how Medicine 3.0 may evolve. These trends are driven by advances in biology, data science, and healthcare infrastructure.

Biological Aging Clocks

Research is increasingly focused on measuring biological age rather than chronological age. This includes:

• DNA methylation clocks
• Metabolic and proteomic markers
• Brain imaging–based age models

These tools attempt to estimate how quickly an individual is aging at a biological level. Early evidence suggests they may correlate with disease risk and mortality, although standardization is still developing (Cell, 2022).

Multi-Modal Risk Models

Single metrics are being replaced by combined models that integrate multiple data streams. For example:

• Combining metabolic, genetic, and imaging data
• Using AI to identify patterns across datasets

These models aim to improve predictive accuracy by capturing different aspects of health simultaneously. However, complexity increases, and interpretability becomes more challenging.

AI-Driven Health Forecasting

Artificial intelligence is being used to analyze longitudinal health data and generate predictive scores related to disease progression or functional decline.

These systems are not deterministic. They provide probabilities based on patterns observed in large datasets, and their reliability depends on data quality and representation (ArXiv Authors, 2023).

Integration of Clinical Care and Research

A notable shift is the move toward continuously learning systems, where clinical data feeds directly into research and vice versa.

In this model:

• Patient data contributes to broader understanding
• Research findings are applied more rapidly in practice

This reduces the gap between discovery and application but raises questions around data governance and consent.

Expansion of Longevity as a Clinical Field

Longevity medicine is gradually emerging as a distinct domain. This includes:

• Dedicated training programs
• Specialized clinical units
• Increased research funding

However, the field is still in an early stage, with varying definitions, standards, and levels of evidence.

Evidence Layer: What the Research Indicates

The scientific foundation of Medicine 3.0 is evolving. While some components are well-supported, others remain exploratory.

Chronic Disease Development Is Long-Term

A consistent finding across epidemiological research is that major chronic diseases develop over extended periods, often influenced by cumulative exposure to risk factors (The Lancet Healthy Longevity, 2021).

This supports the rationale for earlier detection and intervention, even if the optimal methods are still being refined.

Biological Markers Provide Partial Insight

Biomarkers whether genetic, metabolic, or imaging-based offer signals rather than conclusions. They can indicate associations with disease risk but do not always translate into actionable outcomes.

For example:

• Differences between biological and chronological age are associated with mortality risk
• Inflammatory markers correlate with multiple disease pathways

However, the predictive power of individual markers is often limited when used in isolation.

Aging Is Multi-Factorial

Research into the biology of aging suggests that it is driven by multiple interconnected processes, including:

• Cellular damage accumulation
• Chronic inflammation
• Metabolic dysregulation
• Impaired cellular repair mechanisms

These processes interact in complex ways, making single-target interventions less effective (López-Otín et al., 2025).

Data Improves Prediction, Not Certainty

The integration of large datasets and AI models improves the ability to identify patterns and estimate risk. However, predictions remain probabilistic.

Uncertainty is inherent due to:

• Variability between individuals
• Incomplete data representation
• Changing environmental and behavioral factors

Social and Environmental Factors Remain Significant

Evidence also indicates that non-biological factors such as socioeconomic conditions, lifestyle, and early-life environment play a major role in long-term health outcomes.

In some studies, these factors explain more variation in physical and cognitive decline than biological markers alone. This highlights the limits of purely data-driven or biological approaches.

Overall, the evidence base supports the direction of Medicine 3.0, particularly its emphasis on early detection and individualized interpretation. At the same time, it underscores the need for caution, as many tools and models are still developing and require further validation.

Limitations and Considerations

While Medicine 3.0 introduces a more structured approach to early risk detection and long-term health management, it also brings a set of constraints that are often less visible in high-level discussions. Understanding these limitations is central to interpreting the model realistically.

Variability in Evidence Quality

Not all components of Medicine 3.0 are supported by the same level of evidence. Some areas such as cardiovascular risk markers or metabolic indicators are well studied and widely validated. Others, particularly newer biomarkers and aging clocks, remain under active investigation.

This creates an uneven landscape where:

• Some signals are clinically actionable
• Others are exploratory and open to interpretation

As a result, the reliability of conclusions depends heavily on which data is being used and how it is interpreted (López-Otín et al., 2025).

Interpretation Complexity

Collecting more data does not necessarily lead to clearer decisions. In many cases, it increases complexity.

Multiple data streams genomic, metabolic, behavioral may produce signals that:

• Overlap
• Conflict
• Lack clear thresholds

This can make it difficult to distinguish between meaningful risk and normal variation. Even with advanced models, interpretation remains probabilistic rather than definitive.

Risk of Over-Detection

Earlier detection can identify potential issues before they become clinically significant. However, this also introduces the possibility of:

• Identifying conditions that may never progress
• Triggering unnecessary follow-up testing
• Increasing intervention without clear benefit

This phenomenon, often discussed in screening contexts, reflects a broader trade-off between early awareness and over-diagnosis.

Psychological and Behavioral Impact

Access to detailed risk information can influence how individuals perceive their health.

For some, it provides clarity. For others, it may lead to:

• Increased anxiety
• Hyper-focus on minor deviations
• Changes in behavior based on uncertain predictions

There is also concern that highly specific risk predictions could create a self-reinforcing effect, where expectations influence outcomes indirectly.

Data Representation and Bias

Many predictive models are built on datasets that do not fully represent global populations. This creates potential bias in:

• Risk estimation
• Model accuracy
• Applicability across different demographic groups

For example, certain populations remain underrepresented in genomic datasets, which can limit the generalizability of findings (Califf and Hudson, 2021).

Lack of Standardization

Unlike established clinical guidelines, many aspects of Medicine 3.0 lack consistent standards. This includes:

• Which biomarkers to measure
• How frequently to test
• What thresholds to use for action

As a result, approaches can vary significantly between providers, leading to inconsistent experiences and interpretations.

Commercial and Regulatory Gaps

The growing interest in longevity has led to the emergence of services that operate outside traditional regulatory frameworks.

Some offerings may:

• Use off-label therapies
• Promote interventions with limited evidence
• Combine clinical and experimental approaches

This does not invalidate the model, but it does require careful distinction between evidence-based practice and experimental application.

Cost and Accessibility

Many components of Medicine 3.0 advanced diagnostics, continuous monitoring, personalized analysis are resource-intensive.

This creates barriers related to:

• Cost
• Availability
• Infrastructure

As a result, access is often limited to specific segments of the population, raising questions about scalability and equity.

Taken together, these limitations do not negate the potential of Medicine 3.0. Instead, they define the boundaries within which it currently operates. The model introduces new capabilities, but also new forms of uncertainty that must be interpreted with care.

Who This Is For — and Who It Is Not

Medicine 3.0 is not universally applicable in the same way traditional healthcare is. Its value depends on context particularly how an individual approaches risk, uncertainty, and long-term planning.

More Aligned With

This model tends to align with individuals who:

• Think in long-term horizons, often planning across decades
• Are comfortable working with probabilistic information, rather than clear yes/no answers
• Have an interest in data-driven self-awareness, including tracking and interpretation
• Are willing to engage in ongoing monitoring, rather than one-time interventions

In many cases, these are individuals managing high levels of responsibility, where maintaining consistent physical and cognitive performance is a priority.

Less Aligned With

Medicine 3.0 may be less relevant for individuals who:

• Prefer clear, standardized medical pathways with defined guidelines
• Are not interested in engaging with continuous data or long-term tracking
• Find uncertainty or probabilistic risk difficult to interpret or act upon
• Are primarily focused on short-term treatment outcomes, rather than long-term risk management

This does not limit access to care, but it affects how useful the model is in practice.

Context Matters More Than Category

Rather than being defined by age or health status alone, suitability is shaped by:

• Decision style (analytical vs. directive)
• Risk tolerance (comfort with uncertainty)
• Time perspective (short-term vs. long-term focus)

Medicine 3.0 is less about eligibility and more about alignment with how decisions are made and interpreted.

Decision Framework: Interpreting Options in Practice

Given the range of tools, services, and levels of evidence involved, the central challenge is not access but interpretation. A structured approach can help reduce decision friction.

Step 1: Define the Objective

The first distinction is between different types of goals:

• Diagnosis (identifying an existing condition)
• Risk assessment (estimating future probability)
• Optimization (improving current function or resilience)

Medicine 3.0 is primarily oriented toward the latter two, which often require different types of data and interpretation.

Step 2: Evaluate the Evidence Layer

Not all tools operate at the same level of validation. It is useful to distinguish between:

• Established markers with strong clinical backing
• Emerging indicators with growing but incomplete evidence
• Experimental signals still under research

Understanding where a given test or model sits on this spectrum helps frame expectations around reliability.

Step 3: Assess Interpretation Quality

The value of data depends on how it is interpreted. Key considerations include:

• Whether interpretation is standardized or individualized
• The extent to which multiple data points are integrated
• The transparency of assumptions behind risk models

In many cases, interpretation introduces more variability than data collection itself.

Step 4: Consider Time Horizon

Different decisions operate on different timelines:

• Short-term (months to a few years)
• Medium-term (5–10 years)
• Long-term (decades)

Medicine 3.0 often focuses on longer horizons, where outcomes are less certain and require iterative reassessment.

Step 5: Account for Trade-Offs

Every intervention or monitoring strategy involves trade-offs, including:

• Benefit vs. uncertainty
• Early detection vs. over-detection
• Data depth vs. interpretability

Recognizing these trade-offs helps avoid over-reliance on any single approach.

The Role of Structured Guidance

As the number of variables increases, self-directed interpretation can become difficult to sustain. Some individuals choose to navigate this independently, while others rely on structured frameworks or external guidance to:

• Filter relevant data
• Prioritize signals
• Maintain consistency over time

The distinction is not between right and wrong approaches, but between levels of structure applied to decision-making.

Synthesis

Medicine 3.0 represents a shift in how health is framed—not as a series of isolated events, but as a continuous trajectory shaped by interacting variables over time.

Across its components, several patterns emerge:

• The emphasis moves from treatment to timing
• Data becomes more continuous and individualized
• Interpretation shifts from definitive answers to probabilistic insight
• Decision-making becomes iterative rather than fixed

At the same time, the model introduces new forms of complexity:

• Evidence is uneven across different tools
• Interpretation varies between contexts
• Uncertainty remains inherent, even with advanced data

Rather than simplifying healthcare, Medicine 3.0 reorganizes it—creating a system that is potentially more precise, but also more dependent on how information is structured and understood.

The central challenge is not access to data or technology, but the ability to interpret signals, manage uncertainty, and make context-aware decisions over time.

Final Thoughts

Medicine 3.0 is often described as a shift in tools or technologies, but its deeper change lies in how health is interpreted over time.

It reframes health from a series of isolated clinical events into a continuous, evolving system of signals. Within this system, certainty becomes less central. What matters instead is the ability to work with partial information—interpreting patterns, adjusting assumptions, and revisiting decisions as new data emerges.

This introduces a different kind of discipline. Not one based on fixed protocols, but on structured thinking under uncertainty.

In this context, more data does not automatically create clarity. In many cases, it increases the number of variables that need to be understood. The advantage, then, does not come from access alone, but from how effectively complexity is organized and interpreted.

Medicine 3.0 does not eliminate ambiguity. It makes it more visible—and, in doing so, creates the possibility of managing it more deliberately.

Frequently Asked Questions

Is Medicine 3.0 widely adopted in standard healthcare systems?

In most cases, it is not yet fully integrated into standard healthcare systems. While certain elements such as preventive screening and personalized risk assessment are becoming more common, the broader framework remains fragmented. Adoption varies by region, infrastructure, and clinical setting, and many components are still developing.

How reliable are biological age and longevity tests?

Biological age measurements are an active area of research and are generally considered informative but not definitive. Different methods such as DNA methylation or metabolic markers capture different aspects of aging, which can lead to variation in results. Their usefulness often depends on how they are interpreted within a broader context rather than as standalone indicators.

Does more health data always lead to better decisions?

Not necessarily. While additional data can improve visibility into health patterns, it can also increase complexity. Without structured interpretation, more data may lead to conflicting signals or uncertainty. The value of data depends less on volume and more on how it is contextualized and applied.

Is Medicine 3.0 focused only on wealthy or specialized populations?

At present, access to many components such as advanced diagnostics and continuous monitoring can be resource-dependent. However, the underlying principles are not limited to any specific group. Over time, broader adoption may depend on cost, infrastructure, and standardization across healthcare systems.

How does Medicine 3.0 handle uncertainty in predictions?

Uncertainty is treated as an inherent part of the system rather than something to eliminate. Most predictive models operate on probabilities, not certainties. This means decisions are often made based on likelihood and context, with the understanding that interpretations may change as new data becomes available.

Can early detection of risk lead to unnecessary interventions?

In some cases, yes. Identifying early signals may result in additional testing or monitoring that does not always translate into improved outcomes. This is a recognized trade-off in preventive approaches, where the balance between early awareness and over-detection must be considered carefully.

Closing Perspective

For some, navigating Medicine 3.0 remains a self-directed process assembling information from multiple sources, interpreting signals independently, and making decisions over time.

For others, the challenge is less about access and more about structuring complexity. As the number of variables increases, so does the need for a clearer framework to filter, prioritize, and interpret what matters.

Some platforms now position themselves as a guidance layer within this landscape, helping individuals make sense of available options without acting as providers of treatment. ExtendMyLife operates in this space focusing on organizing information, narrowing relevant pathways, and supporting context-based interpretation through human-led guidance.

In practice, the distinction is not between having information and lacking it, but between navigating complexity alone and applying structure to it.

👉 View Longevity Program
Return to ExtendMy.Life
Back to Top

Disclaimer

This article is intended for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. The concepts discussed, including Medicine 3.0 and longevity science, are part of an evolving field with varying levels of scientific evidence. Interpretations of health data, biomarkers, and predictive models may differ across individuals and clinical contexts. Any decisions related to health should be made in consultation with qualified medical professionals. No personal data is collected or processed through this content. Any external interaction, including messaging platforms, is optional and user-initiated, with privacy considerations remaining the responsibility of the user.

References

Califf, R.M. and Hudson, K.L. (2021) ‘Precision medicine and the future of health care’, New England Journal of Medicine.

Hood, L. and Flores, M. (2012) ‘A personal view on systems medicine and the emergence of proactive healthcare’, New Biotechnology.

López-Otín, C. et al. (2025) ‘Hallmarks of aging revisited: biological markers and interventions’, Experimental & Molecular Medicine.

The Lancet Healthy Longevity (2021) ‘Longevity medicine: redefining healthspan’, The Lancet Healthy Longevity.

ArXiv Authors (2023) ‘Integrative AI-driven strategies for precision medicine’, arXiv.

ArXiv Authors (2024) ‘Deep learning approaches to aging and health modeling’, arXiv.

­